TR200001356T2 - Ateşli hastalıkların transjenerik modelleri - Google Patents
Ateşli hastalıkların transjenerik modelleriInfo
- Publication number
- TR200001356T2 TR200001356T2 TR2000/01356T TR200001356T TR200001356T2 TR 200001356 T2 TR200001356 T2 TR 200001356T2 TR 2000/01356 T TR2000/01356 T TR 2000/01356T TR 200001356 T TR200001356 T TR 200001356T TR 200001356 T2 TR200001356 T2 TR 200001356T2
- Authority
- TR
- Turkey
- Prior art keywords
- interleukin
- mammals
- gene
- knockout
- febrile diseases
- Prior art date
Links
- 208000015220 Febrile disease Diseases 0.000 title 1
- 238000012301 transgenic model Methods 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 4
- 108010063738 Interleukins Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 abstract 1
- 102000015696 Interleukins Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0325—Animal model for autoimmune diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0368—Animal model for inflammation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Mevcut bulus, bir veya daha fazla sayidaki interlökin genlerin ifadesinin bastirildigi bir memeli sunar. Daha spesifik olarak bulus, hastalikli veya ifadesi tamamen bastirilmis endogenez gene sahip nakavt edilmis insan olmayan bir memeli üretmek için interlökin-1 alici antagonist genin inaktivasyon iptaliyle ilgilidir. Bulus, böyle nakavt edilmis memelilerin hazirlanmasi için yöntemler ve nakavt edilmis memelilerin, interlökin yollarindaki düzensizliklerle iliskilendirilen hastaliklarin veya bozukluklarin tedavi edilmesi için olan tedavisel maddelerin ve rejimlerinin etkililiginin degerlendirilmedi amaciyla kullanilmasi için olan yöntemleri sunar.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9723835.6A GB9723835D0 (en) | 1997-11-13 | 1997-11-13 | Interleukin knockout |
Publications (1)
Publication Number | Publication Date |
---|---|
TR200001356T2 true TR200001356T2 (tr) | 2000-08-21 |
Family
ID=10821919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2000/01356T TR200001356T2 (tr) | 1997-11-13 | 1998-11-13 | Ateşli hastalıkların transjenerik modelleri |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1030926A2 (tr) |
JP (1) | JP2001523467A (tr) |
KR (1) | KR20010015814A (tr) |
AU (1) | AU1796699A (tr) |
BR (1) | BR9814142A (tr) |
CA (1) | CA2309807A1 (tr) |
GB (1) | GB9723835D0 (tr) |
HU (1) | HUP0004352A2 (tr) |
IL (1) | IL136013A0 (tr) |
NO (1) | NO20002477L (tr) |
PL (1) | PL340829A1 (tr) |
TR (1) | TR200001356T2 (tr) |
WO (1) | WO1999025857A2 (tr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6437216B1 (en) | 1997-11-13 | 2002-08-20 | Interleukin Genetics Inc. | Transgenic models of inflammatory disease |
WO2001056606A1 (fr) * | 2000-01-31 | 2001-08-09 | Santen Pharmaceutical Co., Ltd. | Remedes pour troubles ophtalmiques |
KR20030067204A (ko) * | 2002-02-07 | 2003-08-14 | 한국생명공학연구원 | 퍼록시레독신-ⅱ 유전자 결손 생쥐 및 이의 생산방법 |
WO2005078098A1 (en) * | 2004-02-12 | 2005-08-25 | The Walter And Eliza Hall Institute Of Medical Research | Modified cells that co-express blimp1 and a reporter molecule and methods of using the same |
JP2009183176A (ja) * | 2008-02-05 | 2009-08-20 | Univ Of Tokyo | Il−1タイプiiレセプター遺伝子の欠損変異体マウス |
JP5186637B2 (ja) * | 2009-07-30 | 2013-04-17 | 国立大学法人富山大学 | トランスジェニック非ヒト哺乳動物およびその利用 |
WO2019235839A1 (ko) * | 2018-06-05 | 2019-12-12 | 사회복지법인 삼성생명공익재단 | 그레이브스 안병증 표현형 동물 모델, 그의 제조방법 및 그레이브스 안병증 치료물질 스크리닝 방법 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1269989B (it) * | 1994-09-21 | 1997-04-16 | Dompe Spa | Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria |
JPH10507637A (ja) * | 1994-10-20 | 1998-07-28 | メルク エンド カンパニー インコーポレーテッド | インターロイキン−1β欠損トランスジェニック動物 |
US6210877B1 (en) * | 1997-03-10 | 2001-04-03 | Interleukin Genetics, Inc. | Prediction of coronary artery disease |
-
1997
- 1997-11-13 GB GBGB9723835.6A patent/GB9723835D0/en not_active Ceased
-
1998
- 1998-11-13 BR BR9814142-2A patent/BR9814142A/pt not_active Application Discontinuation
- 1998-11-13 CA CA002309807A patent/CA2309807A1/en not_active Abandoned
- 1998-11-13 EP EP98962809A patent/EP1030926A2/en not_active Withdrawn
- 1998-11-13 JP JP2000521220A patent/JP2001523467A/ja active Pending
- 1998-11-13 IL IL13601398A patent/IL136013A0/xx unknown
- 1998-11-13 TR TR2000/01356T patent/TR200001356T2/tr unknown
- 1998-11-13 HU HU0004352A patent/HUP0004352A2/hu unknown
- 1998-11-13 KR KR1020007005243A patent/KR20010015814A/ko not_active Application Discontinuation
- 1998-11-13 AU AU17966/99A patent/AU1796699A/en not_active Abandoned
- 1998-11-13 WO PCT/US1998/024287 patent/WO1999025857A2/en not_active Application Discontinuation
- 1998-11-13 PL PL98340829A patent/PL340829A1/xx unknown
-
2000
- 2000-05-12 NO NO20002477A patent/NO20002477L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
GB9723835D0 (en) | 1998-01-07 |
IL136013A0 (en) | 2001-05-20 |
BR9814142A (pt) | 2000-10-03 |
JP2001523467A (ja) | 2001-11-27 |
AU1796699A (en) | 1999-06-07 |
NO20002477D0 (no) | 2000-05-12 |
WO1999025857A3 (en) | 1999-07-15 |
PL340829A1 (en) | 2001-02-26 |
NO20002477L (no) | 2000-07-12 |
EP1030926A2 (en) | 2000-08-30 |
CA2309807A1 (en) | 1999-05-27 |
HUP0004352A2 (en) | 2001-03-28 |
KR20010015814A (ko) | 2001-02-26 |
WO1999025857A2 (en) | 1999-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
van den Berg et al. | Role of tumour necrosis factor α in experimental arthritis: separate activity of interleukin 1β in chronicity and cartilage destruction | |
Dang et al. | SLE-like autoantibodies and Sjögren's syndrome-like lymphoproliferation in TGF-beta knockout mice. | |
Vezzani et al. | Interleukin-1β immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: functional evidence for enhancement of electrographic seizures | |
Hamelmann et al. | IL‐5‐induced airway eosinophilia–the key to asthma? | |
Vezzani et al. | Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice | |
Cook et al. | Granulocyte macrophage colony-stimulating factor receptor α expression and its targeting in antigen-induced arthritis and inflammation | |
EP1245676A4 (en) | HUMANE MONOCLONAL ANTIBODIES AGAINST THE TGF-BETA II RECEPTOR AND THEIR MEDICAL USE | |
WO2003078658A3 (en) | Methods for diagnosing and treating schizophrenia | |
TR200001356T2 (tr) | Ateşli hastalıkların transjenerik modelleri | |
WO2003016499A3 (en) | Combinatorial methods for inducing cancer cell death | |
Ferguson et al. | Different genetic mechanisms mediate spontaneous versus UVR-induced malignant melanoma | |
ATE511401T1 (de) | Kombinierte gentherapie zur behandlung makroskopischer glioma | |
ATE442861T1 (de) | Gegen antikörper gerichtete photodynamische therapie | |
Lapointe et al. | Group V secreted phospholipase A2 contributes to LPS‐induced leukocyte recruitment | |
Zhang et al. | Netrin‐G2 and netrin‐G2 ligand are both required for normal auditory responsiveness | |
Gao et al. | Kdm6b haploinsufficiency causes ASD/ADHD-like behavioral deficits in mice | |
EE9900275A (et) | CD40L-vastaste ühendite terapeutilise manustamise meetodid | |
Barbarese et al. | Conditional knockout of tumor overexpressed gene in mouse neurons affects RNA granule assembly, granule translation, LTP and short term habituation | |
Ito et al. | Exacerbation of pathogenic Th17-cell-mediated cutaneous graft-versus-host-disease in human IL-1β and IL-23 transgenic humanized mice | |
Marongiu et al. | Reversible disruption of pre-pulse inhibition in hypomorphic-inducible and reversible CB1-/-mice | |
Achatz‐Straussberger et al. | Limited humoral immunoglobulin E memory influences serum immunoglobulin E levels in blood | |
EA200700346A1 (ru) | Бактериофаг- и профаг-специфические протеины в генной терапии рака | |
AU2002350745A1 (en) | Non-human transgenic mammals used as models for human pathologies originating from stem cells | |
DK0858807T3 (da) | Anvendelse af dopaminreceptor-antagonister i palliativ tumorterapi | |
Kripke | Delayed Circadian rhythms and pars tuberalis dysfunction in mood disorders |